trending Market Intelligence /marketintelligence/en/news-insights/trending/hEFMAoLpugPu__iqr73d7w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Ono Pharmaceutical's fiscal Q1 profit slips YOY despite increase in revenue

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Ono Pharmaceutical's fiscal Q1 profit slips YOY despite increase in revenue

Ono Pharmaceutical Co. Ltd. reported fiscal first-quarter consolidated profit attributable to shareholders of ¥11.77 billion, or ¥22.31 per share, down from ¥13.68 billion, or ¥25.81 per share in the year-ago period.

Revenue for the three months from April through June reached ¥60.91 billion, up from ¥58.76 billion in the previous year. The company's revenue from Japan fell year over year to ¥48.40 billion from ¥53.70 billion, and rose in the Americas and Asia during the period.

Ono booked ¥14.94 billion in research and development costs during the quarter, up from ¥11.12 billion in the year-ago period.

Sales for the cancer blockbuster drug Opdivo jumped 21.4% to ¥19.80 billion in the quarter and are expected to reach ¥74.0 billion for the full fiscal year ending March 31, 2018.

The Japanese pharmaceutical company confirmed its outlook for the full fiscal year: attributable profit of ¥29.0 billion, or ¥54.72 per share, and revenue of ¥236.0 billion.

For the the first six months of the fiscal year, Ono expects revenue to reach ¥112.50 billion with profit attributable to shareholders of ¥10.70 billion, or ¥20.19 per share.

As of Aug. 1, US$1 was equivalent to ¥110.15.